4/11/2017 The Castleman Disease Collaborative Network announced a collaboration with Janssen Research & Development, LLC, to conduct a proteomics study of idiopathic multicentric Castleman disease (iMCD). The Press Release in BusinessWire stated “the collaboration combines CDCN’s strong expertise in iMCD research and its world-wide network of physician researchers with Janssen’s industry leading iMCD research resources”. During this study, collaborators will measure the “level of approximately 1,300 analytes in more than 260 serum samples collected from approximately 100 iMCD patients at various time points during active disease.” Read the full press release here.
CDCN Partners with Janssen for Proteomics Study
The CDCN has partnered with Janssen Research and Development to help fund and conduct new Castleman disease research.